Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Northwestern University Feinberg School of Medicine, Chicago, IL, United States

Survival: 17.4 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Chicago, IL
Hospital: Northwestern University Feinberg School of Medicine
Journal: Link
Date: 1/2013

This phase 2 study involved female HER2-negative advanced breast cancer patients who were divided into two separate treatment groups. Group A had 119 patients with an average age of 50.6 years. Group B had 118 patients with a median age of 53.1 years.

Patients in group A were treated with the chemotherapy agent paclitaxel and the biologic therapy agent sorafenib, which is a multikinase inhibitor that interferes with cancer cell growth.

Patients in group B were treated with paclitaxel and a placebo.

Adverse event-related deaths were reported in group A; causes included malaria, liver dysfunction, and heart attack. Grade 4 neutropenia, mucosal inflammation, and shortness of breath were also reported.

There were three adverse event-related deaths in group B due to meningitis and an unknown cause. Grade 4 neutropenia and grade 3 nerve toxicities were also reported.

The median overall survival for group A and B was 16.8 and 17.4 months, respectively.

This study was partially supported by Onyx Pharmaceuticals and Bayer Healthcare Pharmaceuticals.

Correspondence: Dr. William J. Gradishar; email:

E-mail to a Friend Email Physician More Information